17 Exenatide showed a trend-level indication of lowering HbA1c in the study. 17 Exenatide and liraglutide have been extensively studied and have demonstrated promising outcomes in reducing cardiometabolic complications in patients undergoing antipsychotic treatment. 17 Therefore, the use of GLP-1 receptor agonists presents a promising strategy to mitigate the cardiometabolic complications associated with antipsychotic treatment.
← all excerpts
The Potential Role of GLP-1 Agonists in Psychiatric Disorders: A Paradigm Shift in Mental Health Treatment.
1
—
—